PHYSICIAN AWARENESS AND INDICATIONS OF 5-ALPHA REDUCTASE INHIBITOR USE FOR BENIGN PROSTATIC HYPERPLASIA IN THE PRIMARY CARE SETTING

被引：0
|
作者：
Loloi, J. [1 ]
Alicea, D. [2 ]
Babar, M. [2 ]
Shah, J. [2 ]
Azhar, U. [2 ]
Labagnara, K. [2 ]
Salam, A. [2 ]
Tang, K. [2 ]
Robles, J. [1 ]
Maria, P. [1 ]
机构：
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
JOURNAL OF SEXUAL MEDICINE | 2024年 / 21卷
关键词：
D O I：
10.1093/jsxmed/qdae167.213
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
218
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men
    Chang, Jooyoung
    Choi, Seulggie
    Kim, Kyuwoong
    Park, Sang Min
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (05)
  • [32] Dutasteride:: a novel dual inhibitor of 5α-reductase for benign prostatic hyperplasia
    Djavan, B
    Milani, S
    Fong, YK
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (02) : 311 - 317
  • [33] Combination of α-blocker and 5 α-reductase Inhibitor for treatment of benign prostatic hyperplasia
    Kang, Deying
    Hu, Caoyang
    Fu, Yanyan
    Wang, Dongwen
    CLINICAL AND INVESTIGATIVE MEDICINE, 2017, 40 (05): : E200 - E210
  • [34] Dutasteride -: A potent dual inhibitor of 5α-reductase for benign prostatic hyperplasia
    Rabasseda, X
    DRUGS OF TODAY, 2004, 40 (08) : 649 - 661
  • [35] The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
    Ayodele, Olulade
    Cabral, Howard J.
    McManus, David
    Jick, Susan
    CLINICAL EPIDEMIOLOGY, 2021, 13 : 661 - 673
  • [36] TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH 5-ALPHA-REDUCTASE INHIBITORS
    STONER, E
    GUESS, H
    ENDOCRINOLOGIST, 1995, 5 (02): : 140 - 146
  • [37] 5-ALPHA-REDUCTASE INHIBITORS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
    STONER, E
    RECENT PROGRESS IN HORMONE RESEARCH, VOL 49, 1994, 49 : 285 - 292
  • [38] Tadalafil versus tamsulosin as combination therapy with 5-alpha reductase inhibitors in benign prostatic hyperplasia, urinary and sexual outcomes
    Tawfik, Ahmed
    Abo-Elenen, Mohammed
    Gaber, Mohammed
    El-Abd, Ahmed
    Zoeir, Ahmed
    Saad, Sayed
    Sultan, Intessar
    Ghoneim, Ayman
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
  • [39] Current Situation in the Use of 5-Alpha Reductase Inhibitors for Prostatic Diseases
    Kosan, Murat
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2014, 13 (04): : 244 - 246
  • [40] Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride
    Golchin-Rad, Kamran
    Mogheiseh, Asghar
    Nazifi, Saeed
    Khafi, Mohammad Saeed Ahrari
    Derakhshandeh, Nooshin
    Abbaszadeh-Hasiri, Mohammad
    TOPICS IN COMPANION ANIMAL MEDICINE, 2020, 38
12345